Vaginal pessary use is an established, non-surgical treatment option for pelvic organ prolapse. While satisfaction rates are initially high, they seem to decline over time. We aimed to determine the median duration of pessary use among our patients and to evaluate reasons for discontinuation. All patients who were treated with a vaginal pessary for pelvic organ prolapse between 2007 and 2022 at our institution (a maximum observation period of 15years) were included in this retrospective cohort study. Data were collected from the in-house electronic databases and the date of pelvic floor surgery was defined as the primary endpoint. In case of no documented surgery, the date of the last follow-up visit (for patients lost to follow-up or who discontinued pessary use without subsequent surgery) or the date of final data collection (for those with presumed continued pessary use) was used as the primary endpoint. Duration of pessary use is represented by Kaplan-Meier curves. Effects of possible confounders were investigated by Cox regression models. A Cox regression model was evaluated for patients with the three most common types of pessary: ring, cube and shell. A chi-square test was performed to compare therapy adherence according to pessary type. Data of 779 patients could be included in the statistical analysis. The estimated median duration of pessary use was 173weeks (95% CI 104-473) - approximately 3.3years. Overall, 30% of patients opted for surgical therapy and the majority of them did so within 4months of initiation of pessary use (median time: 19weeks, 95% CI 16-26). In 5% of cases a discontinuation of pessary use without subsequent surgery was documented and 18% were lost to follow-up before a planned visit, thus leaving 47% of our patients with presumed continued pessary use. Possible confounding factors for discontinuation of pessary use were tested but were found to be non-significant (body mass index, Pelvic Organ Prolapse - Quantification score, pelvic floor training, age, parity, menopausal status, nicotine consumption, incontinence or size of pessary). Reasons for discontinuation of pessary use were documented in 51% of patients: unspecified patient wish (23%), pessary use tiredness (10%), general dissatisfaction with pessary therapy (7%), unspecified reasons (5%), pessary self-change not possible (1%), erosion, bleeding, pain (2%); none of the pessary types fitted (2%). According to our data, almost half of our patients with pelvic organ prolapse and pessary therapy continued pessary use until a maximum follow-up time of 15years, whereas about one-third of patients finally opted for surgical repair (a majority of these within 4months after pessary therapy initiation). The remaining patients were either lost to follow-up or discontinued pessary use without subsequent surgery. The stated reasons for discontinuation of pessary use were mostly non-specific, but only 1% reported that pessary self-change was not possible. Erosion bleeding or pain was documented in only 2% of cases as reason for discontinuation. This information helps clinicians to inform their patients with pelvic organ prolapse about expected pessary therapy success and strengthens individual counselling. Furthermore, our data indicates vaginal pessary use for pelvic organ prolapse is feasible and safe for all women and that therapy adherence can extend beyond 5years.